Top

Published in:

01-04-2017 | Original Article – Clinical Oncology

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

Title: Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up
Publication date: 01-04-2017
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2334-x

ACC 2024 Congress Coverage

Heart Failure Video

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

16-04-2024 Type 2 Diabetes News

11-04-2024 Lifestyle Modifications News

10-04-2024 Myocardial Infarction News